Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer

CAMBRIDGE, Mass.--()--Agilis Biotherapeutics, LLC, a synthetic biology-based company focused on developing DNA-based therapeutics for rare genetic diseases, announced today that Greg Robinson, Ph.D., has been named Chief Scientific Officer of the Company. Dr. Robinson brings more than 20 years of pharmaceutical and biotech experience in research, clinical development, R & D management and business roles to Agilis, having spent the last seven years at Shire PLC (LSE:SHP; NASDAQ GS:SHPG) where he served as Head of Discovery Research and more recently as Senior Director, Shire Rare Diseases Business Development.

“The experience that Dr. Robinson brings to the Agilis team is directly aligned with Agilis’ mission and will help us advance our rare disease pipeline,” said Mark Pykett, President and CEO of Agilis Biotherapeutics. “Dr. Robinson is highly accomplished in his field and brings Agilis extensive management and leadership experience along with a record of strong scientific achievement and particular expertise in the development of genetic therapies. We look forward to working closely with Greg in the development of life changing medicines.”

Dr. Robinson’s efforts in identifying new opportunities were highlighted by his key role in the identification and acquisition of two rare disease companies while at Shire: Lotus Tissue Repair for dystrophic epidermolysis bullosa and Premacure for retinopathy of prematurity. Prior to his tenure at Shire, he was Senior Director of Drug Discovery at Eyetech Pharmaceuticals, which went public in 2004, achieved FDA approval of a treatment for macular degeneration and was later acquired by OSI Pharmaceuticals. Before Eyetech, Dr. Robinson was Director of Drug Discovery and Project Leader of Ophthalmology at Pharmacia Corporation. Dr. Robinson received his Ph.D. from Boston University and completed post doctorate studies at Dana Farber Cancer Institute, Harvard Medical School. He has authored more than 13 issued patents and has co-authored over 40 peer-reviewed publications.

“I am eager to join Agilis at this very exciting time,” said Dr. Robinson. “The Company is well positioned to develop best-in-class gene therapy medicines. With its advancing gene therapy platform, an outstanding Scientific Advisory Board and an enabling collaboration with Intrexon, a leader in synthetic biology, I believe Agilis is at the forefront of advanced breakthrough treatments."

About Agilis Biotherapeutics, LLC

Agilis Biotherapeutics, LLC, is a biotechnology company focused on designing and engineering best-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are limited or no treatment options. We believe that engineered DNA-based therapeutics provide the ability to target underlying disease mechanisms with tightly-controlled multigenic modalities leading to “functional cures” for patients with these diseases.

We invite you to visit our website at www.agilisbio.com

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

Contacts

Agilis Biotherapeutics
Dr. Jodi Cook, 510-673-7809
Vice President, Operations
jcook@agilisbio.com

Contacts

Agilis Biotherapeutics
Dr. Jodi Cook, 510-673-7809
Vice President, Operations
jcook@agilisbio.com